JCI – Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Top Tools Go to PDF
Top Tools Go to PDF
Pathologic complete response after neoadjuvant treatment in pancreatic ductal adenocarcinoma is a rare occurrence. Similar to other malignancies, achieving a pathologic complete response in pancreatic…
A flawed study attracted grants, investments and other researchers who based new work on the faulty findings.
Abstract. KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC); however, resistance is common. Among patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib,…
PURPOSE Immunotherapies have shown limited responses in patients with advanced pancreatic cancer. Recently, we reported that dendritic cell (DC)–based immunotherapy induced T-cell responses against pancreatic…
AbstractLessons Learned. The safety profile in the gemcitabine/simtuzumab group was similar to that in the gemcitabine/placebo group.The addition of simtuz
Texans voted in 2007 to create the Cancer Prevention & Research Institute of Texas (CPRIT) and to invest $3 billion in the state’s unprecedented fight…
Identifying the key molecular pathways that enable metastasis by analyzing the eventual metastatic tumor is challenging because the state of the founder subclone likely changes…
Nature Metabolism – Multi-omics analysis of mouse livers shows that protein β-hydroxybutyrylation (Kbhb) is strongly affected by the ketogenic diet. Combining bioinformatics with experimental…
For years, people at risk of severe allergic reaction have had to rely on epinephrine auto-injectors like EpiPens. The FDA just approved the first nasal…
For years, people at risk of severe allergic reaction have had to rely on epinephrine auto-injectors like EpiPens. The FDA just approved the first nasal…